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and Ludmila A. Frank*ab
Two obelin mutants distinctly diﬀerent in the color of bioluminescence were successfully applied to
simultaneous detection of two analytes in a single well. The ﬂash-type signals were triggered by single
injection of Ca2+ and were discriminated by the spectral and time resolutions. The technique was
developed in a high-throughput format, and applied to simultaneous immunoassay of two
gonadotropic hormones – luteinizing (lutropin or hLH) and follicle stimulating (hFSH) – in clinical sera,
and to simultaneous detection of two gene allelic variants at single nucleotide polymorphism
genotyping of the human F5 gene encoding factor V Leiden polymorphism 1691 G/A (R506Q). A
considerable number of samples were investigated and the results obtained were in good correlation
with those obtained by using traditional techniques.Introduction
Ca2+-regulated photoprotein obelin, like other coelenterate
photoproteins, is a stable complex of a single-chain apoprotein
and peroxycoelenterazine. Upon binding of Ca2+, obelin
undergoes a conformation change that causes the decarboxyl-
ation of peroxycoelenterazine and the emission of visible light
(lmax ¼ 482 nm).1,2 The relationship between the light emission
and the amount of obelin is linear in the presence of an excess
of Ca2+. A high quantum yield of the reaction, virtual absence of
the background, and high sensitivity of modern photometers
make it possible to detect the photoprotein down to the atto-
mole level. The recently developed analytical techniques use
Ca2+-regulated photoproteins aequorin and obelin as eﬀective
reporters.3 Binding assays involving these bioluminescent
reporters provide high sensitivity, simplicity of measurement,
reproducibility and safety. With the application of site-directed
mutagenesis, obelin mutants with substantially altered biolu-
minescence spectral and kinetic characteristics were obtained
in our laboratory: W92F,H22E emits a fast (kd ¼ 0.6 s1) violet
signal (lmax ¼ 387 nm) and Y138F – a slow (kd ¼ 6.1 s1)
greenish light (lmax¼ 498 nm) with small spectral overlapping.4
Using these as reporters, we developed a dual analyte single-well
bioluminescence assay based on the spectral resolution of
signals, in combination with time resolution. The techniquephysics, Russian Academy of Sciences,
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0allows enhancement of the assay capability for the sake of
proper diagnostics, especially in cases requiring the detection of
two analytes in one sample.
Recently, we successfully applied the approach to the
simultaneous immunoassay of two forms of prolactin, the total
and IgG-bound ones, in crude serum.5 It was performed in a
microplate format and allowed the detection of the two
prolactin forms without any additional manipulation. The assay
provided a high sensitivity in detecting total prolactin, close to
that of RIA, and a capability to visualize both prolactin forms
like in the case of gel-ltration chromatography, but in a much
shorter time.
In this study, the application of our approach was broadened
to: (a) simultaneous immunoassay of two gonadotropic
hormones – luteinizing (lutropin or hLH) and follicle stimu-
lating (hFSH) – in clinical sera, and (b) simultaneous detection
of two gene allelic variants at SNP genotyping of the human F5
gene encoding factor V Leiden polymorphism 1691 G/A
(R506Q). Many clinical samples were investigated and the
obtained results were in good correlation with those obtained
by traditional techniques.Experimental
Materials
The highly puried photoproteins (violet mutant W92F,H22E
and green mutant Y138F of obelin) were obtained according to
ref. 4. Streptavidin, 2-iminothiolan, N-succinimidyl-4-(N-mal-
eimidomethyl)cyclohexane-1-carboxylate (SMCC) were from
Sigma (USA).
Monoclonal mouse anti-hLH IgG (clone 5301) and anti-
hFSH IgG (clone 6602) were from MedixBiochemica (Finland);This journal is ª The Royal Society of Chemistry 2013
Paper Analytical Methodsmonoclonal mouse anti-hLH/hFSH (a-chain) IgG (clone XF-1) –
from Xema-Medica (Russia); goat polyclonal anti-FITC IgG –
from Abcam (UK). The standard sera (calibrated according to
hLH WHO 1st IRP 68/40 and hFSH WHO 2nd IRP 78/549) were
from DIAS (Russia).
Biotinyl uridine triphosphate (B-dUTP), oligothymidine,
carrying a 50-hexamethylamino group, 50-NH2-(CH2)6-p-T30,
(NH2-dT30); primers for amplication of genomic DNA: 50-
CATCATGAGAGACATCGCCTC-3’ (LeiUp) and 50-CATGTTC-
TAGCCAGAAGAAATTC-30 (LeiDn), primers for the PEXT reac-
tion: 50-FAM-AGCAGATCCCTGGACAGGCG-30 (LeiN) and 50-
(A)27AGCAGATCCCTGGACAGGCA-30 (LeiM) were obtained from
Biosan (Russia). Hot Start Taq DNA polymerase and dNTPs were
from SibEnzyme (Russia). SNPdetect polymerase was from
Evrogen (Russia).
Conjugates W92F,H22E-anti-hLH IgG (clone 5301), Y138F-
anti-hFSH IgG (clone 6602), and Y138F-anti-FITC IgG were
synthesized according to the method described in ref. 6.
To obtain the W92F,H22E-(dT)30 conjugate, the protein was
incubated with a 5-fold excess of 2-iminothiolan in 50 mM
BICINE pH 8.5, 5 mM EDTA for 30 min at room temperature.
Excess of reagent was removed by gel ltration on a D-salt
Dextran Desalting column (Pierce, USA) equilibrated with
50 mM PIPES pH 7.5, 5 mM EDTA. The NH2-dT30 was modied
by a 100-fold excess of SMCC in 0.1 M NaHCO3 for 2 h at room
temperature followed by removal of excess reagent on a
Sephadex G-25 spin-column equilibrated with water. The
mixture of thionylated W92F,H22E and SMCC-activated oligo-
nucleotide (molar ratio 2 : 1) was incubated overnight at 8 C.
The conjugate W92F,H22E-(dT)30 was puried on a Mono Q
column (GE Healthcare, Sweden) equilibrated with 20 mM Tris–
HCl pH 7.0, 5 mM EDTA using gradient 1 M NaCl up to 70%.
All conjugates were stored at 18 C in 20 mM Tris–HCl pH
7.0, 0.25 M NaCl, 5 mM EDTA, 0.1% BSA over 1 year without loss
of bioluminescent activity.
Solid-phase immunoassay was carried out using white
polystyrene stripwell microtiter plates (Corning, USA). In dual
color assays, the photometer registered signals through band-
pass optical lters VB6 (I) and YB16 (II) (Len-ZOS, Russia).
Sera samples were provided by the endocrinology diagnostic
laboratory of Krasnoyarsk regional hospital no. 1. The hLH and
hFSH in sera were previously quantied with separate RIA.
DNA samples were analyzed earlier by other methods and
provided by Krasnoyarsk Branch of Hematological Scientic
Center of the Russian Academy of Medical Sciences.
Simultaneous microtiter-based bioluminescent immuno-
assay of LH and FSH. The surface of wells was activated with
100 mL of mouse anti-hLH/hFSH (a-chain) (clone XF-1) immu-
noglobulin solution, 10 mg mL1, in PBS (0.15 M NaCl, 50 mM
K–Na phosphate buﬀer pH 7.0) overnight at 4 C. Then it was
washed (three times, PBS, 0.1% Tween 20, 5 mM EDTA) and
blocked by placing 1% BSA in PBS (140 mL per well) for 1 h,
37 C. Aer washing, 100 mL standard (three replicates) and
clinical (two replicates) sera were placed into the wells, incu-
bated with shaking for 1 h at 37 C and washed thereaer. Then
the mixture of conjugates – W92F,H22E-anti-hLH IgG (clone
5301) and Y138F-anti-hFSH IgG (clone 6602) (100 mL, 1 mg mL1This journal is ª The Royal Society of Chemistry 2013each, PBS, 0.1% BSA, 5 mM EDTA) – was placed into the wells,
incubated with shaking for 1 h at 23 C and washed thereaer.
The bioluminescence was measured with a plate luminometer
LB 940 Multimode Reader Mithras (Berthold, Germany) by
rapid injection of CaCl2 solution (100 mL, 0.1 M in 0.1 M Tris–
HCl, pH 8.8) into the well. The measurements were carried out
as follows: during the rst second the photometer registered the
violet signal transmitted through lter I; the replacement of
lter II took the next 0.3 s; the green light was registered for the
last 5 seconds.
Amplication of genomic DNA. Amplication of genomic
DNA was carried out in 25 mL buﬀer containing 67 mM Tris–
HCl, pH 8.8, 16.6 mM (NH4)2SO4, 0.01% Tween 20, 2 mMMgCl2,
dNTPs (0.2 mM each), the LeiUp and LeiDn primers (0.4 mM
each), genomic DNA (1–10 ng), and Hot Start Taq DNA poly-
merase (2.5 U). PCR conditions: denaturation at 95 C for 5 min,
then 30 cycles at 95 C for 30 s, 55 C for 30 s, and 72 C for 40 s
followed by heating of the reaction mixture at 72 C for 10 min.
PCR products were analyzed by electrophoresis in 1.7% agarose
gel and stained with ethidium bromide. Concentration of PCR
products was evaluated using the densitometry image of an
electropherogram with Alpha EasyTM soware (Alpha Innotech
Corporation, USA). DNA Ladder 100 bp + 50 bp (SibEnzyme,
Russia) was used as a calibration marker.
PEXT reaction. PEXT reaction was performed in 20 mL of a 1
SNP detect buﬀer containing 2.5 mM MgCl2, dATP, dCTP,
dGTP, B-dUTP (2.5 mM each), DNA template (0.2 pmol), LeiN
and LeiM primers (1 pmol each), and SNP detect DNA poly-
merase (2 U). The reaction conditions were: denaturation at
95 C for 5 min, then 3 cycles at 95 C for 15 s, 60 C for 10 s,
and 72 C for 15 s followed by heating of the reaction mixture at
95 C for 5 min.
PEXT products microplate assay. The surface of the wells was
activated with 50 mL of streptavidin solution, 10 mg mL1, in PBS
for 1 h at 37 C with shaking. Aer washing (three times, PBS,
0.1% Tween 20, 5 mM EDTA) the PEXT products (3 mL) in
hybridization buﬀer (47 mL) containing 0.1 M maleic acid, 0.15
M NaCl, 5 mM EDTA, and 1% BSA were placed into the wells
and incubated for 30 min at room temperature. The wells were
washed again and the mixture of conjugates, Y138F-anti-FITC
IgG and W92F,H22E-(dT)30 (50 mL, each 0.1 mg mL
1, in 20 mM
Tris–HCl pH 7.0, 5 mM EDTA, 0.1 M NaCl, 0.1% BSA), was
placed into the wells, incubated with shaking for 30 min at
room temperature and washed thereaer. The bioluminescence
intensity was measured with a plate luminometer LB 940
Multimode Reader Mithras by rapid injection of CaCl2 solution
into the well plate as was described above, excepting the green
signal integrated for 3 seconds.Results and discussion
Two kinds of the mutant of Ca2+-regulated photoprotein obelin
recently obtained in our laboratory4 are characterized by their
distinct diﬀerence in bioluminescence. The emission maxima
of mutants W92F,H22E (violet) and Y138F (green) are separated
by 113 nm with a small spectral overlap. It is possible to exploit
this wide separation by the use of two wide band-pass opticalAnal. Methods, 2013, 5, 636–640 | 637
Fig. 1 Bioluminescence of the mixture of obelin mutants transmitted through
ﬁlter I (fast violet signal) and ﬁlter II (slow green signal); dashed line, time for ﬁlter
replacement. Upper inset: bioluminescence spectra of obelin mutants (thick lines)
and optical ﬁlter transmission (thin lines). r.l.u. – relative light units.
Fig. 2 (A). Schematic representation of the simultaneous solid-phase
immunoassay of gonadotropic hormones. (B). Data output. Wells A1–C7, stan-
dard sera assay (in triplicates). Rows A1–A7, concentrations of hormones. Other
cells present clinical sera assays (in two replicates each). (C and D) Bioluminescent
standard sera microtiter-based immunoassay of hFSH (based on green signals)
and hLH (based on violet signals), respectively. Each point is an average  1
standard deviation (n ¼ 3). (E and F) Correlation of hFSH and hLH concentrations
in 71 clinical samples obtained with simultaneous bioluminescent (BLIA) and
separate isotopic (RIA) assays.
Analytical Methods Paperlters (Fig. 1, inset). Because the bioluminescence kinetics of
the green obelin is 10-fold slower than that of the violet obelin,
the diﬀerence provides the possibility to resolve the signals in
time. To implement the separation methods, we applied a plate
luminometer Mithras LB 940. The construction of this device
facilitates luminescence measurement through the optical
lters placed on the wheel that allows fast lter replacement.
Fig. 1 shows the bioluminescent reaction of the proteinmixture.
To divide signals eﬀectively, a fast-kinetic violet signal was
registered through optical lter I for 1 s, and a long-kinetic
green signal – through optical lter II for 3–5 seconds. Filter
replacement was done automatically for 0.3 seconds.
Human luteinizing hormone (lutropin or hLH) and follicle
stimulating hormone (hFSH) belong to a subset of glycoprotein
hormones, called gonadotropins that regulate gonadal func-
tion. Immunoassay is a useful tool for estimating the hormone
levels in serum, and is important for discovering the disorders
related to reproduction and puberty, such as hypogonadism,
ovulation timing, and infertility. For proper diagnosis, it is
strongly recommended to measure the levels of both hormones.
The hLH and hFSH contain two diﬀerent subunits, an a- and a
b-chain, linked by noncovalent bonds. The primary structures
of the a-subunits are almost identical, while their b-subunits are
not identical. The b-subunits are responsible for the immuno-
logical and biological specicity of these hormones.
Fig. 2A presents the way we carried out the assay. The surface
of wells was activated with immunoglobulin Ab1 (anti-hLH/
hFSH, a-chain), then the samples of standard or clinical sera
were placed into the wells, incubated and washed. The mixture
of Y138F-Ab2 (anti-hFSH immunoglobulin) and W92F,H22E-
Ab3 (anti-hLH immunoglobulin) conjugates was placed into the
wells, incubated and washed thereaer. The violet label got
bound with the hLH b-subunit, whereas the green one bound
with the hFSH b-subunit. Bioluminescence of both labels was
triggered by Ca2+ injection and measured sequentially: during
the rst second the violet signal was integrated through lter I,
and aer lter replacement the green signal was measured for 5638 | Anal. Methods, 2013, 5, 636–640seconds. Fig. 2B gives the typically obtained results. The assay
(in triplicate) of standard sera was performed in wells A1–C7.
These samples are articial sera, containing hLH and hFSH of a
given equal concentration. The dependences of the violet
bioluminescent signal upon hLH concentration and the green
signal upon hFSH concentration (Fig. 2C and D) are linear forThis journal is ª The Royal Society of Chemistry 2013
Fig. 3 (A) Schematic representation of PEXT reaction. (B) Simultaneous
solid-phase assay of PEXT reaction products. (C) Data output on the assay of six
clinical DNA samples. (D) Results of genotyping of 1691 G/A polymorphism in
F5 gene (69 samples). St – streptavidin; B – biotinyl; FAM – ﬂuorescein; BLN/BLM –
green to violet bioluminescent signal ratio.
Paper Analytical Methodsthe whole concentration range, with R2 ¼ 0.999 and R2 ¼ 0.997,
respectively. The hLH and hFSH bioluminescence assay sensi-
tivities were 0.4 mU mL1 and 0.34 mU mL1 respectively
(calculated from three replicates of standard zero sera assay, as
mean + 2 standard deviation). These are close to sensitivities of
separate radioisotope immunoassay – 0.34 mU mL1 for hLH
and 0.28 for hFSH (diagnostic kit from DIAS Ltd, Russia), and
colorimetric immunoassay (0.3 mU mL1, diagnostic kit from
XEMA, Russia). Using these dependence data as calibration
curves, we determined the hLH and hFSH concentrations in 71
clinical sera. Some sera assays (in duplicate each) are presented
in wells D1–H7. The data demonstrate good correlation between
the proposed simultaneous bioluminescent assay and the
traditional separate RIA (Fig. 2E and F): R2¼ 0.92, slope¼ 1.1 in
the case of hLH and R2¼ 0.94, slope¼ 0.88 in the case of hFSH.
Another type of assay requiring detection of two targets (two
gene allelic variants) is single nucleotide polymorphism (SNP)
genotyping. We developed the method for SNP identication
based on the primer extension reaction (PEXT)7 followed by
simultaneous alleles detection with bioluminescent solid-phase
microassay. The study was performed as an example of SNP
genotyping factor V Leiden polymorphism 1691 G/A (R506Q)
in the gene encoding coagulation factor V. Identication of this
polymorphism has prognostic value, which allows one to esti-
mate the risk of cardiovascular diseases caused by blood clot-
ting disorders and cardiovascular abnormalities in oﬀspring.
Coagulation factor V is the protein cofactor in the formation of
thrombin from prothrombin. Mutation confers the resistance
to the active form of factor V against proteolytic action of the
regulating enzyme (activated protein C), which leads to hyper-
coagulation. Carriers of variant A have an increased propensity
to vascular thrombosis, which represents a risk factor for
venous and arterial thromboembolism, myocardial infarction,
and stroke. This polymorphism is diagnostically valuable and
widely analyzed in laboratory diagnostics.
Specially selected DNA samples analyzed earlier by other
methods were taken for the investigation. Genomic DNA was
amplied by PCR using primers anking a polymorphic site of
140 base pairs (dbSNP: rs6025). PCR products were used as
templates for PEXT reaction with two primers containing 30-
terminal nucleotides, which were complementary to either
normal or mutant alleles (Fig. 3A). The primer complementary
to the normal allele was labeled with 6-carboxyuorescein
(FAM), the other with oligoadenylate (dA)27. The reactions were
carried out in the same tube. If the template and allele-specic
primer were completely complementary, the latter was elon-
gated with DNA polymerase. The resulting extension product
contained a biotin residue due to the presence of biotinylated
deoxyuridine triphosphate (B-dUTP) in the reaction mixture.
The products were analyzed by solid-phase microassay in the
same microtiter well according to the scheme presented in
Fig. 3B. Biotin-containing oligonucleotides were immobilized
on the streptavidin-activated well surface. Then the conjugate
mixture (violet obelin–oligothymidylate and green obelin–anti-
FAM IgG) was placed into the wells, incubated and washed.
Obelins' bioluminescent reaction was initiated by Ca2+ and
measured as was described above. The green signal isThis journal is ª The Royal Society of Chemistry 2013associated with the normal allele, while the violet one is
associated with mutant allele availability. The genotype for each
sample is dened by the ratio of the bioluminescent signals.
Fig. 3C shows the assay of six clinical samples – three of them
have normal genotype (with an average signals' ratio, BLN/BLM,
of 18), whereas another three have a heterozygous genotype
(with an average signals' ratio, BLN/BLM, about 1.6). The devel-
oped method was applied to investigate 69 clinical samples
(Fig. 3D): 24 of them were of normal genotype, the others of
heterozygous genotype. The samples with homozygous muta-
tion have not been identied since this genotype is very rare.
The results coincided completely with the real-time PCR data
obtained by the staﬀ of the Hematology Research Center
(Krasnoyarsk Branch of the RAMS).
Reproducibility of themethod was evaluated from the results
of triplicate analysis (PCR of genomic DNA, PEXT reaction, and
bioluminescent analysis of the reaction products) of two DNA
samples of G/A and G/G genotypes. The variation coeﬃcient of
the discrimination factor (BLN/BLM) was 10.5% for the hetero-
zygous G/A genotype and 14.4% for the normal G/G genotype.
There are no essential changes in the discrimination factor
over a broad range of amplied DNA amount in PEXT reactions.Anal. Methods, 2013, 5, 636–640 | 639
Analytical Methods PaperSo at assaying 10, 25, 50, 100 and 200 fmol of amplied DNA,
the average discrimination factor values were 15.4  2.85 and
1.58  0.45 for G/A and G/G genotype samples, respectively.
Conclusion
In the present study, we have successfully applied two obelin
mutants for simultaneous detection of two analytes in a single
well, based on the spectral and time resolutions of biolumi-
nescent signals. Both ash-type signals were triggered by a
single injection of Ca2+ – no other substrates or co-factors were
required. The total registration took only 4–6 s, despite the fact
that the bioluminescence of labels was integrated sequentially.
This distinguishes the proposed approach from the two-target
simultaneous assays involving two diﬀerent labels [e.g. see ref.
8–10]. We see obvious reasons for applying this technique in any
dual assay regardless of its type – immune, hybridization or
both. It is useful for large-scale research, and provides a fast and
sensitive two-target assay that overcomes shortcomings of
separate determination, in addition to the advantages in terms
of cost and labor savings.
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